title: Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
abstract: OBJECTIVE
  Gynecologic Oncology Group Study 0218 (GOG-0218), a phase III, placebo-controlled trial in newly diagnosed stage III/IV ovarian cancer (OC), demonstrated a benefit in investigator (INV)-assessed progression-free survival (PFS) with bevacizumab (BEV) administered with and following carboplatin/paclitaxel (CP) for up to 15 months vs. CP alone. To determine the reliability of Response Evaluation Criteria in Solid Tumors (RECIST) in assessing disease progression (PD) in GOG-0218, an independent review of radiologic and clinical data (IRC) was conducted.
  
  
  METHODS
  Blinded reviews followed RECIST 1.0 in accordance with the study protocol; PFS was analyzed in the intent-to-treat population.
  
  
  RESULTS
  CP+BEV→BEV achieved a significant PFS improvement in both assessments. Hazard ratios for PFS (IRC: 0.623; 95% confidence interval [CI]: 0.503-0.772; p<0.0001 vs. INV: 0.624; 95% CI: 0.520-0.749; p<0.0001) and the improvement in median PFS (IRC: 19.1 and 13.1 months vs. INV: 18.2 and 12 months) were similar between IRC and INV assessments. There was high concordance between IRC- and INV-determined PD status (77%) and date (73%). Subgroup analyses were consistent with the primary IRC findings. Early and late discontinuation discordance measures showed no evidence of INV bias.
  
  
  CONCLUSIONS
  IRC analysis confirmed a significant PFS improvement with CP+BEV→BEV vs. CP alone. Concordance was not influenced by extent of residual disease after cytoreductive surgery or initial stage. The IRC size, high participation rate, and strong concordance between IRC and INV assessments suggest that RECIST can be applied objectively in OC studies.
authors.affiliation: Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: robert.a.burger@fccc.edu.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Burger
authors.forename: Mark F
authors.initials: MF
authors.lastname: Brady
authors.forename: Joon
authors.initials: J
authors.lastname: Rhee
authors.forename: Mika A
authors.initials: MA
authors.lastname: Sovak
authors.forename: George
authors.initials: G
authors.lastname: Kong
authors.forename: Hoa P
authors.initials: HP
authors.lastname: Nguyen
authors.forename: Michael A
authors.initials: MA
authors.lastname: Bookman
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005185:Fallopian Tube Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000601:surgery; D015588:Observer Variation; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000601:surgery; D011859:Radiography; D016037:Single-Blind Method
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
keywords: Bevacizumab; IRC; Independent review; Ovarian cancer; Phase 3
references.citation: Eur J Cancer. 2011 Aug;47(12):1772-8
references.pmid: 21429737
references.citation: Lancet. 2006 Oct 14;368(9544):1329-38
references.pmid: 17046465
references.citation: N Engl J Med. 2011 Dec 29;365(26):2473-83
references.pmid: 22204724
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Clin Cancer Res. 2006 Dec 15;12(24):7271-8
references.pmid: 17189398
references.citation: Int J Gynecol Cancer. 2011 May;21(4):750-5
references.pmid: 21543936